Replimune Says Stockholders Approved Amendment To Increase Authorized Common Shares From 150M To 300M, Effective September 15
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001737953/000110465926108243/tm2625488d1_8k.htm
Stocks · News reference
The aggregate gross proceeds from the offering are expected to be approximately $150 million, before deducting underwriting discounts and commissions and other offering expenses. All of the securities in the offering
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001737953/000110465926108243/tm2625488d1_8k.htm
Filed: 2026-09-16 AccNo: 0001104659-26-108243 Size: 215 KB Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 9.01: Financial Statements and Exhibits
JP Morgan analyst Anupam Rama maintains Replimune Group (NASDAQ:REPL) with a Overweight and raises the price target from $20 to $21.
-SEC Filing